Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has launched a new clinical program into the use of its daily oral cannabinoid-based drug to potentially treat Rett Syndrome in female patients.
The program will comprise a filing for Human Research Ethics Committee (HREC) approval and the commencement of a phase two clinical trial investigating the use of lead candidate NTI164 in up to 15 female patients aged from five to 20 years.
Read a full text here.
Neurotech International to launch clinical program into use of lead drug NTI164 to treat Rett Syndrome